This approval allows Zydus Lifesciences to enter the promising US market, where Leuprolide Acetate injection generates $69 million in annual sales, the company said.
This approval allows Zydus Lifesciences to enter the promising US market, where Leuprolide Acetate injection generates $69 million in annual sales, the company said.